| Advanced Waldenström's macroglobulinemia: usefulness of Morel's scoring system in establishing prognosis. | |
| | |
MedLine Citation:
|
PMID: 15710594 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
New treatments for patients with Waldenstrom's macroglobulinemia (WM) have necessited the development of prognostic indices. Using a sample of 92 patients with refractory or relapsing WM treated in a randomized trial, we show that Morel's prognostic scoring system for patients at diagnosis is also effective in patients with advanced disease. |
| | |
Authors:
|
Vincent Lévy; Pierre Morel; Raphaël Porcher; Sylvie Chevret; Eric Wattel; Véronique Leblond |
Related Documents
:
|
11971224 - Successful treatment of pure red cell aplasia with plasmapheresis in a patient with sys... 2611124 - Mucosal involvement in systemic and chronic cutaneous lupus erythematosus. 18306484 - Successful etanercept therapy for refractory sacroiliitis in a patient with ankylosing ... 3581694 - Systemic lupus erythematosus: follow-up study of 148 patients. i: classification, clini... 20430204 - Extracoporeal membrane oxygenation hybrid with thoratec ventricular-assist devices as d... 22118944 - Young alzheimer patients show distinct regional changes of oscillatory brain dynamics. |
Publication Detail:
|
Type: Letter; Randomized Controlled Trial |
Journal Detail:
|
Title: Haematologica Volume: 90 ISSN: 1592-8721 ISO Abbreviation: Haematologica Publication Date: 2005 Feb |
Date Detail:
|
Created Date: 2005-02-15 Completed Date: 2006-08-09 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0417435 Medline TA: Haematologica Country: Italy |
Other Details:
|
Languages: eng Pagination: 279-81 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Antineoplastic Agents / pharmacology Cohort Studies Cyclophosphamide / administration & dosage Doxorubicin / administration & dosage Drug Therapy, Combination Humans Male Middle Aged Multivariate Analysis Prednisone / administration & dosage Prognosis Time Factors Vidarabine / analogs & derivatives, therapeutic use Waldenstrom Macroglobulinemia / diagnosis*, therapy* |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 21679-14-1/fludarabine; 23214-92-8/Doxorubicin; 50-18-0/Cyclophosphamide; 53-03-2/Prednisone; 5536-17-4/Vidarabine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Lack of receptor activator of nuclear factor-kB ligand (RANKL) expression and functional production ...
Next Document: Effect of a single dose of rituximab in chronic immune thrombocytopenic purpura in childhood.